Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Texas Neurology, PA
mi
from
Dallas, TX
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Texas Neurology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Innovative Clinical Trials
mi
from
San Antonio, TX
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Innovative Clinical Trials
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Integra Clinical Research
mi
from
San Antonio, TX
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Integra Clinical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Vista Infusions
mi
from
San Antonio, TX
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Vista Infusions
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Inventive Infusion Solutions
mi
from
San Antonio, TX
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Inventive Infusion Solutions
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
Click here to add this to my saved trials
Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers
Improving Affect and Behavior in Assisted Living Residents
Status: Enrolling
Updated:  11/30/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers
Improving Affect and Behavior in Assisted Living Residents
Status: Enrolling
Updated: 11/30/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers
Improving Affect and Behavior in Assisted Living Residents
Status: Enrolling
Updated:  11/30/2015
Rush University School of Nursing
mi
from
Chicago, IL
Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers
Improving Affect and Behavior in Assisted Living Residents
Status: Enrolling
Updated: 11/30/2015
Rush University School of Nursing
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  12/2/2015
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 12/2/2015
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  12/2/2015
Comprehensive NeuroScience, Inc.
mi
from
St. Petersburg, FL
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 12/2/2015
Comprehensive NeuroScience, Inc.
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  12/2/2015
Memory Center of New Jersey, Inc.
mi
from
Monroe Twp, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 12/2/2015
Memory Center of New Jersey, Inc.
mi
from
Monroe Twp, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  12/2/2015
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 12/2/2015
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  12/2/2015
Senior Adults Specialty Research
mi
from
Austin, TX
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 12/2/2015
Senior Adults Specialty Research
mi
from
Austin, TX
Click here to add this to my saved trials
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated:  12/2/2015
Clinica Santa Maria, Div Neurologia
mi
from
Castellanza,
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment
Status: Enrolling
Updated: 12/2/2015
Clinica Santa Maria, Div Neurologia
mi
from
Castellanza,
Click here to add this to my saved trials
Effects of Simvastatin on Biomarkers
Effects of Simvastatin on CSF AD Biomarkers in Cognitively Normal Subjects
Status: Enrolling
Updated:  12/2/2015
VA Puget Sound Health Care System
mi
from
Seattle, WA
Effects of Simvastatin on Biomarkers
Effects of Simvastatin on CSF AD Biomarkers in Cognitively Normal Subjects
Status: Enrolling
Updated: 12/2/2015
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
African American Alzheimer's Progression Markers - CSF and Neuro-Imaging
Status: Enrolling
Updated:  12/3/2015
Emory University
mi
from
Atlanta, GA
African American Alzheimer's Progression Markers - CSF and Neuro-Imaging
Status: Enrolling
Updated: 12/3/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Dedicated Clinical Research
mi
from
Goodyear, AZ
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Dedicated Clinical Research
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Jeffrey S. Gitt, DO, PC
mi
from
Phoenix, AZ
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Jeffrey S. Gitt, DO, PC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
The Compounding Center (IP Mixing Only)
mi
from
Phoenix, AZ
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
The Compounding Center (IP Mixing Only)
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
HOPE Research Institute
mi
from
Phoenix, AZ
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
HOPE Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Clinical Trials, Inc.
mi
from
Little Rock, AR
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Clinical Trials, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
ATP Clinical Research, Incorporated
mi
from
Costa Mesa, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
ATP Clinical Research, Incorporated
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Pharmacology Research Institute
mi
from
Encino, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Pharmacology Research Institute
mi
from
Encino, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Margolin Brain Institute
mi
from
Fresno, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Margolin Brain Institute
mi
from
Fresno, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Infusion Care Pharmacey
mi
from
Laguna Hills, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Infusion Care Pharmacey
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Senior Clinical Trials, Incorporated
mi
from
Laguna Hills, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Senior Clinical Trials, Incorporated
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Faculty Physicians and Surgeons of Loma Linda University School of Medicine
mi
from
Loma Linda, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Faculty Physicians and Surgeons of Loma Linda University School of Medicine
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Pharmacology Research Institute
mi
from
Newport Beach, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Pharmacology Research Institute
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Coordinated Clinical Research
mi
from
San Diego, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Coordinated Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
LabCorp
mi
from
San Diego, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
LabCorp
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Sharp and Children's MRI Center, LLC
mi
from
San Diego, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Sharp and Children's MRI Center, LLC
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Sharp Infusion Therapy Center
mi
from
San Diego, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Sharp Infusion Therapy Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Sharp Memorial Hospital
mi
from
San Diego, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
San Francisco Clinical Research Center
mi
from
San Francisco, CA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
San Francisco Clinical Research Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Alpine Clinical Research Center
mi
from
Boulder, CO
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Alpine Clinical Research Center
mi
from
Boulder, CO
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Associated Neurologists, PC
mi
from
Boulder, CO
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Associated Neurologists, PC
mi
from
Boulder, CO
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Mile High Research Center
mi
from
Denver, CO
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Mile High Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Associated Neurologists, P.C.
mi
from
Danbury, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Associated Neurologists, P.C.
mi
from
Danbury, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Bendheim Cancer Center
mi
from
Greenwich, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Bendheim Cancer Center
mi
from
Greenwich, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Center for Healthy Aging
mi
from
Greenwich, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Center for Healthy Aging
mi
from
Greenwich, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Yale University School of Medicine
mi
from
New Haven, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
Yale-New Haven Hospital
mi
from
New Haven, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials